The acquisition creates a leading cell therapy solutions provider, combining differentiated platforms and expanding offerings in a high-growth market. The $1.5B deal is accretive to growth, margins, and EPS, with clear synergies and a straightforward integration plan.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.